Title |
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
|
---|---|
Published in |
Frontiers in immunology, April 2017
|
DOI | 10.3389/fimmu.2017.00386 |
Pubmed ID | |
Authors |
Paola Queirolo, Beatrice Dozin, Anna Morabito, Barbara Banelli, Patrizia Piccioli, Cristiana Fava, Claudio Leo, Roberta Carosio, Stefania Laurent, Vincenzo Fontana, Pier Francesco Ferrucci, Chiara Martinoli, Emilia Cocorocchio, Angelo Battaglia, Paolo A. Ascierto, Mariaelena Capone, Ester Simeone, Federica De Galitiis, Elena Pagani, Gian Carlo Antonini Cappellini, Paolo Marchetti, Michele Guida, Stefania Tommasi, Mario Mandalà, Barbara Merelli, Pietro Quaglino, Paolo Fava, Massimo Guidoboni, Massimo Romani, Francesco Spagnolo, Maria Pia Pistillo |
Abstract |
Ipilimumab (IPI) blocks CTLA-4 immune checkpoint resulting in T cell activation and enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of patients with metastatic melanoma (MM). We investigated the association of CTLA-4 single nucleotide variants (SNVs) with best overall response (BOR) to IPI and OS in a cohort of 173 MM patients. Patients were genotyped for six CTLA-4 SNVs (-1661A>G, -1577G>A, -658C>T, -319C>T, +49A>G, and CT60G>A). We assessed the association between SNVs and BOR through multinomial logistic regression (MLR) and the prognostic effect of SNVs on OS through Kaplan-Meier method. Both -1577G>A and CT60G>A SNVs were found significantly associated with BOR. In particular, the proportion of responders was higher in G/G genotype while that of stable patients was higher in A/A genotype. The frequency of patients experiencing progression was similar in all genotypes. MLR evidenced a strong downward trend in the probability of responsiveness/progression, in comparison to disease stability, as a function of the allele A "dose" (0, 1, or 2) in both SNVs with reductions of about 70% (G/A vs G/G) and about 95% (A/A vs G/G). Moreover, -1577G/G and CT60G/G genotypes were associated with long-term OS, the surviving patients being at 3 years 29.8 and 30.8%, respectively, as compared to 12.9 and 14.4% of surviving patients carrying -1577G/A and CT60G/A, respectively. MM patients carrying -1577G/G or CT60G/G genotypes may benefit from IPI treatment in terms of BOR and long-term OS. These CTLA-4 SNVs may serve as potential biomarkers predictive of favorable outcome in this subset of patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Singapore | 1 | 25% |
Switzerland | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 19% |
Student > Bachelor | 3 | 11% |
Professor | 3 | 11% |
Student > Master | 3 | 11% |
Student > Ph. D. Student | 2 | 7% |
Other | 6 | 22% |
Unknown | 5 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 37% |
Biochemistry, Genetics and Molecular Biology | 7 | 26% |
Agricultural and Biological Sciences | 2 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Nursing and Health Professions | 1 | 4% |
Other | 2 | 7% |
Unknown | 4 | 15% |